Non-Hodgkin lymphoma (differentiating types of NHL): Difference between revisions
Preeti Singh (talk | contribs) No edit summary |
Preeti Singh (talk | contribs) No edit summary |
||
Line 16: | Line 16: | ||
! colspan="6" rowspan="2" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestations | ! colspan="6" rowspan="2" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestations | ||
! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings | ! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ||
|- | |- | ||
Line 39: | Line 38: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ||
! colspan="2" align="center" style="background:#DCDCDC;" color: #FFFFFF;" + |[[Hodgkin's lymphoma|Hodgkin's Lymphoma]] | ! colspan="2" align="center" style="background:#DCDCDC;" color: #FFFFFF;" + |[[Hodgkin's lymphoma|Hodgkin's Lymphoma]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 54: | Line 52: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan=" | ! colspan="16" align="center" style="background:#7d7d7d; color: #FFFFFF;" + |Non-Hodgkin's Lymphoma | ||
|- | |- | ||
| | | | ||
Line 73: | Line 71: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Painless rapidly enlarging [[lymph nodes]] | * Painless rapidly enlarging [[lymph nodes]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Extranodal involvement of GI tract, lungs, and CNS | |||
| align="center" style="background:#F5F5F5;" + |↓ | | align="center" style="background:#F5F5F5;" + |↓ | ||
| align="center" style="background:#F5F5F5;" + |↓ | | align="center" style="background:#F5F5F5;" + |↓ | ||
| align="center" style="background:#F5F5F5;" + |Nl to ↓ | | align="center" style="background:#F5F5F5;" + |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* CD20 | |||
* CD3 | |||
* CD5 | |||
* CD45 | |||
* CD10 | |||
* BCL-2 | |||
* BCl-6 | |||
* MYC | |||
* IRF-4/ MUM-1 | |||
* Ki-67 | |||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
'''Centroblastic''' | '''Centroblastic''' | ||
Line 87: | Line 96: | ||
'''Anaplastic''' | '''Anaplastic''' | ||
*Very large cells with a round, oval, or polygonal shape that may resemble Reed-Sternberg cells | *Very large cells with a round, oval, or polygonal shape that may resemble Reed-Sternberg cells | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
Line 121: | Line 129: | ||
* Germinal centers filled by small-to-medium atypical lymphocytes | * Germinal centers filled by small-to-medium atypical lymphocytes | ||
* Nodular appearance | * Nodular appearance | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
Line 141: | Line 148: | ||
| align="center" style="background:#F5F5F5;" + |↓ | | align="center" style="background:#F5F5F5;" + |↓ | ||
| align="center" style="background:#F5F5F5;" + |Nl to ↓ | | align="center" style="background:#F5F5F5;" + |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 176: | Line 182: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Nodular growth pattern | * Nodular growth pattern | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Most common clinically indolent NHL | * Most common clinically indolent NHL | ||
Line 217: | Line 222: | ||
* [[basophilic]] cytoplasm | * [[basophilic]] cytoplasm | ||
* "Starry-sky pattern" | * "Starry-sky pattern" | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
Line 223: | Line 227: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 241: | Line 244: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 278: | Line 280: | ||
* Epithelial histocytes | * Epithelial histocytes | ||
* Plasmacytic differentiation of neoplastic cells | * Plasmacytic differentiation of neoplastic cells | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
Line 299: | Line 300: | ||
* Follicular cells in reactive zone | * Follicular cells in reactive zone | ||
* Centrocyte like cells in marginal zone lymphoma | * Centrocyte like cells in marginal zone lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 310: | Line 310: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 369: | Line 368: | ||
* Central round [[nucleus]] | * Central round [[nucleus]] | ||
* Peri-nuclear clearing ("water-clear rim" appearance) | * Peri-nuclear clearing ("water-clear rim" appearance) | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | | | ||
Line 387: | Line 385: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ||
|- | |- | ||
Line 394: | Line 391: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Precursor T-cell Lymphomas | * Precursor T-cell Lymphomas | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 411: | Line 407: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 428: | Line 423: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 464: | Line 458: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cutaneous manifestations | * Cutaneous manifestations | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 477: | Line 470: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 494: | Line 486: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 511: | Line 502: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 528: | Line 518: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 545: | Line 534: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 562: | Line 550: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 16:09, 18 January 2019
Non-Hodgkin lymphoma Microchapters |
Differentiating Non-Hodgkin's Lymphoma |
---|
Treatment |
Case Studies |
Non-Hodgkin lymphoma (differentiating types of NHL) On the Web |
American Roentgen Ray Society Images of Non-Hodgkin lymphoma (differentiating types of NHL) |
Non-Hodgkin lymphoma (differentiating types of NHL) in the news |
Blogs on Non-Hodgkin lymphoma (differentiating types of NHL) |
Risk calculators and risk factors for Non-Hodgkin lymphoma (differentiating types of NHL) |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Overview
Non-Hodgkin lymphoma (differentiating types of NHL)
Differentiating different types of Non-Hodgkin lymphoma. Gold standard for differentiation different types of Non-Hodgkin lymphoma is Biopsy.
Category | Disease | Etiology | Clinical manifestations | Paraclinical findings | Associated findings | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lab findings | |||||||||||||||
Symptoms | Signs | CBC | Immunochemistry | Histopathology | |||||||||||
Constitutional symptoms | Rash | Abdominal pain | Diarrhea | Mass | Other | WBC | Hb | Plt | |||||||
Hodgkin's Lymphoma | |||||||||||||||
Non-Hodgkin's Lymphoma | |||||||||||||||
Diffuse large B cell lymphoma |
|
|
- | + | + |
|
|
↓ | ↓ | Nl to ↓ |
|
Centroblastic
Immunoblastic
Anaplastic
|
|||
B Cell Lymphoma | Mantle cell lymphoma |
|
|
Abdominal distention |
|
|
|
↓ | Nl to ↓ |
|
|
||||
B-lymphoblastic leukemia/lymphoma |
|
+ | – | – | – |
|
↓ | ↓ | Nl to ↓ |
| |||||
Follicular lymphoma |
|
Only in 20% of patients: | + | + | ± |
|
↓ | ↓ | Nl to ↓ |
|
|
| |||
Burkitt lymphoma |
|
|
|
|
|||||||||||
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma |
|
||||||||||||||
Marginal zone lymphoma | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type |
|
|||||||||||||
Splenic marginal zone lymphoma |
|
|
|||||||||||||
Nodal marginal zone B-cell lymphoma |
|
+ |
|
|
| ||||||||||
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) |
|
||||||||||||||
Hairy cell leukemia |
|
|
|
||||||||||||
Category | Disease | Etiology | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | Mass | Other | WBC | Hb | Plt | Immunochemistry | Histopathology | Associated findings | |
T cell lymphoma | Precursor T-cell lymphoblastic leukemia/lymphoma |
|
|||||||||||||
Adult T cell leukemia/lymphoma |
|
||||||||||||||
Anaplastic large cell lymphoma |
|
||||||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
|||||||||||
Peripheral T-cell lymphoma | Subcutaneous panniculitis-like T-cell lymphoma |
|
|||||||||||||
Hepatosplenic gamma-delta T-cell lymphoma |
|
||||||||||||||
Enteropathy-type intestinal T-cell lymphoma |
|
||||||||||||||
Extranodal T-cell lymphoma, nasal type |
|
||||||||||||||
Angioimmunoblastic T-cell lymphoma |
|
||||||||||||||
Peripheral T-cell lymphoma, unspecified |
|